Inficure Bio has recently signed an agreement with a publicly listed pharmaceutical manufacturer in the US.

The deal is twice as large as the previous record-breaking deal signed last spring with a company in Switzerland.

“This is a fantastic opportunity for us. Deals like this demonstrate that our international credibility is increasing”, says Sofia Mayans, CEO of Inficure Bio. “All business deals are of course important, but the one we have signed now with this US company really stands out. It is significantly larger than any deal we have negotiated so far. It is also an indication that our impact on the international pharmaceutical industry is increasing.”

Easier and faster

Inficure Bio has developed a process that makes it easier and faster for pharmaceutical companies to test drugs that treat fibrosis, which is scar tissue in organs. Scar tissue occurs when the organ is damaged, and a common cause of organ damage is inflammation of the tissue. While fibrosis in itself may not be a serious health problem, uncontrolled fibrosis can result in organ failure. An example of this is when the development of fatty liver drives a constant inflammation that in turn leads to large amounts of fibrosis and liver failure.

The opportunity to get long-term repeat business

“The US company is investing heavily in treatment of fibrosis and has many substances under development. This deal gives us the opportunity to get long-term repeat business as it is likely the company want to test more substances if the tests we are currently conducting prove promising. Customers like this provide us with stability and the opportunity to continue to develop,” says Sofia Mayans. “Our focus has mainly been on the US, Europe and Australian markets but we are currently also working on the introduction of our model into the Korean market. This will certainly broaden our market opportunities and potential revenues.”

Photo of Sofia Mayans and Dan Holmberg, the founders of Inficure Bio. Photographer: Maria Hörnberg